Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies
The Oncologist · 09.03.2026 · 31 (4)
DOI: 10.1093/oncolo/oyag020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 03.02.2026. Verfasst von Aki Inase und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan. Hauptthemen laut MEDLINE: Immunoconjugates, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Antibody-drug conjugates (ADCs) combine a tumor antigen-specific monoclonal antibody with a cytotoxic payload via a linker, enabling selective delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissues. This approach has revolutionized cancer treatment; however, despite these advantages, resistance to ADCs has emerged as a significant barrier to long-term efficacy.
Methods
In this review, we summarize and analyze molecular pathways implicated in ADC resistance across multiple cancer types, including triple-negative breast cancer, non-small cell lung cancer, pancreatic cancer, and relapsed/refractory acute myeloid leukemia. We further examine emerging strategies to overcome resistance, with particular emphasis on combination therapies and the development of next-generation ADCs.
Results
Accumulating evidence indicates that identifying and targeting key resistance-associated pathways can expand the population of patients who benefit from ADC therapy and extend the therapeutic lifespan of these agents. We highlight representative preclinical studies that have elucidated resistance mechanisms and demonstrate potential approaches to restore or enhance ADC efficacy.
Conclusion
Understanding and overcoming ADC resistance is essential as these agents continue to expand into new therapeutic settings. By bridging basic mechanistic insights with translational and preclinical evidence, this review provides a comprehensive framework for addressing ADC resistance and informs future strategies for optimizing cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, United States.
- Timele Clinic, Tokyo, 167-0022, Japan.
- Pelotonia Institute for Immuno-Oncology, OSUCCC - James, The Ohio State University, Columbus, OH, 43210, United States.
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, United States.
- Cancer Center, Kobe University Hospital, Kobe, 650-0017, Japan.
ORCID-Profile: Aki Inase, Mitch A Phelps
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Inase, A., Kimbara, S., Imamura, E., Phelps, M. A., & Minami, H. (2026). Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies. The Oncologist, 31(4). https://doi.org/10.1093/oncolo/oyag020
Vancouver
Inase A, Kimbara S, Imamura E, Phelps MA, Minami H. Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies. The Oncologist. 2026;31(4). doi:10.1093/oncolo/oyag020
BibTeX
@article{Inase2026,
author = {Inase, Aki and Kimbara, Shiro and Imamura, Eli and Phelps, Mitch A and Minami, Hironobu},
title = {Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {4},
doi = {10.1093/oncolo/oyag020}
}
EUVIMED